MRKR

1.09017.42%
KK

Katharine Knobil

Independent Director

Dr. Katharine Knobil, also known as Kate, M.D., is Director and Member of Scientific Advisory Board of Infinant Health, Inc. And also, Chief Medical Officer of Altesa BioSciences Inc from May 2025. She is Independent Director of Korro Bio, Inc. since August 28, 2024. Dr. Knobil is Director of Nimbus Therapeutics, LLC since February 2024. She Currently serves on the Board of KorroBio, Inc. Dr. Knobil is a seasoned executive with broad experience in pharmaceutical research and product development including global clinical research, medical affairs and patient safety. Dr. Knobil serves as Independent Director at Marker Therapeutics, Inc. since December 2021. She served as Independent Director at Pliant Therapeutics, Inc. since September 15, 2022 until June 11, 2026. She served as the Director of Arena Pharmaceuticals, Inc. since June 2020 until March 11, 2022. She served as Chief Medical Officer at Agilent Technologies, Inc. since April 2021 until January 2024. She served as Chief Medical Officer and Head of Research & Development at Kaleido BioSciences, Inc. since December 2018 until January 29, 2021. Dr. Knobil joined Kaleido in December 2018. Dr. Knobil spent many years in roles of increasing responsibility at GlaxoSmithKline (GSK) and was its Chief medical officer from November 2015 to December 2018, overseeing medical affairs, health outcomes, global clinical safety and medical governance across the pharmaceutical, vaccines and consumer businesses. Dr. Knobil first joined GSK in 1997 as a research physician in respiratory clinical development and subsequently held a number of roles, including leading the European respiratory clinical team and building the late-stage clinical development for all therapeutic areas in China. During her time with GlaxoSmithKline, she represented the company at multiple health-regulatory agencies in several countries and led presentations for eight U. S. Food and Drug Administration Advisory Committee Meetings. She has experience in clinical development and medical affairs while serving in strategic leadership roles across the globe. She has led development and medical affairs functions in the U. S. Europe and in emerging markets. She was named one of 2018's Fiercest Women in Life Sciences by FiercePharma. She has served on the Board of Directors of the National Health Council and has been active with the National Academies of Sciences, Engineering and Medicine and the Patient Centered Outcomes Research Institute. Dr. Knobil received her B. A. in Biological Sciences from Cornell University, her M. D. from University of Texas Southwestern Medical School and completed her residency at the University of Michigan Medical School and her fellowship in pulmonary and critical care medicine at Johns Hopkins University School of Medicine.

Positions